(1R,4S)- N-BOC-4-氨基环戊-2-烯甲酸 | 151907-80-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1R,4S)- N-BOC-4-氨基环戊-2-烯甲酸
• 中文别名: (1R,4S)-N-BOC-4-氨基环戊-2-烯甲酸；(1R,4S)-4-(叔丁氧羰基氨基)环戊-2-烯甲酸；(+)-(1R,4S)-N-BOC-4-氨基环戊-2-烯羧酸；(1R,4S)-N-Boc-4-氨基环戊-2-烯甲酸
• 英文名称: (1R,4S)-N-tert-butoxycarbonyl-4-aminocyclopent-2-ene-1-carboxylic acid
• 英文别名: (cis)-4-((tertbutoxycarbonyl)amino)cyclopent-2-ene-1-carboxylic acid；(1R,4S)-4-((tert-butoxycarbonyl)amino)cyclopent-2-enecarboxylic acid；(1R,4S)-N-tert-butoxycarbonyl-1-aminocyclopent-2-ene-4-carboxylic acid；(1R,4S)-4-[(tert-butoxycarbonyl)amino]cyclopent-2-ene-1-carboxylic acid；(1R,4S)-4-(tert-butoxycarbonyl)aminocyclopentane-2-encarboxylic acid；(1R,4S)-4-tert-butyoxycarbonylamino-cyclopent-2-enecarboxylic acid；(4S,1R)-(+)-4-N-boc-aminocyclopent-2-ene-1-carboxylic acid；(1R,4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopent-2-ene-1-carboxylic acid
• CAS: 151907-80-1
• 化学式: C₁₁H₁₇NO₄
• 分子量: 227.26
• InChiKey: WOUNTSATDZJBLP-JGVFFNPUSA-N

物化性质

• 熔点：
  152°C
• 沸点：
  382.3±42.0 °C(Predicted)
• 密度：
  1.18

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (+)-(1R,4S)-N-Boc-4-aminocyclopent-2-enecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (+)-(1R,4S)-N-Boc-4-aminocyclopent-2-enecarboxylic acid
CAS number: 151907-80-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H17NO4
Molecular weight: 227.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1R,4S)- N-BOC-4-氨基环戊-2-烯甲酸 在 palladium 10% on activated carbon 盐酸 、 氢气 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 DMF (N,N-dimethyl-formamide) 、 二氯甲烷 为溶剂， 反应 4.33h， 生成 benzyl (1S,3R)-3-((diphenylmethylene)amino)cyclopentane-1-carboxylate
  参考文献：
  名称：

  [EN] TETRAHYDROPYRANYL CYCLOPENTYL 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  [FR] MODULATEURS TETRAHYDROPYRANYLE CYCLOPENTYLE DE TETRAHYDROISOQUINOLINE 1 SUBSTITUEE ET 1,1-DISUBSTITUEE DE L'ACTIVITE DES RECEPTEURS DE CHIMIOKINE

  摘要：

  公开号：

  WO2005110409A3
• 作为产物：
  描述：

  2-氮杂双环[2.2.1]庚-5-烯-3-酮 在 盐酸 、 水 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 27.0h， 生成 (1R,4S)- N-BOC-4-氨基环戊-2-烯甲酸
  参考文献：
  名称：

  用于折叠聚体和肽纳米管的环状γ-氨基酸的合成

  摘要：

  环状γ-氨基酸是肽和折叠体化学中非常受关注的分子构建块，因为它们允许制备自然界中未发现的新结构。在本文中，我们描述了在氨基和羧酸基团之间具有顺式关系的环状 γ-氨基酸的合成。在大多数情况下，这种排列会导致生成的肽采用扁平构象，这使得它们适用于采用 β-折叠型结构的折叠体的设计。

  DOI：

  10.1002/ejoc.201201565

文献信息

• 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
  申请人：Xue Chu-Biao

  公开号：US20060004018A1

  公开（公告）日：2006-01-05

  The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及以下式的化合物： 这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
• [EN] NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF<br/>[FR] NOUVEAUX INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV, LEUR PROCEDES DE PREPARATION ET COMPOSITIONS EN COMPORTANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2005075426A1

  公开（公告）日：2005-08-18

  The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors or general formula (1) useful for treating diabetes, non-insulin dependent diabetes mellitus, impaired glucose tolerance, inflammatory bowel disease, ulcerative colitis,Chron’s disease, obesity, and metabolic syndrome.

  本发明涉及一种新型二肽基肽酶IV（DPP-IV）抑制剂，其一般式（1）用于治疗糖尿病、非胰岛素依赖型糖尿病、糖耐量受损、炎症性肠病、溃疡性结肠炎、克罗恩病、肥胖症和代谢综合征。
• Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
  作者：Curt D. Haffner、Adam K. Charnley、Christopher J. Aquino、Linda Casillas、Máire A. Convery、Julie A. Cox、Mark A. Elban、Nicole C. Goodwin、Peter J. Gough、Pamela A. Haile、Terry V. Hughes、Beth Knapp-Reed、Constantine Kreatsoulas、Ami S. Lakdawala、Huijie Li、Yiqian Lian、David Lipshutz、John F. Mehlmann、Michael Ouellette、Joseph Romano、Lisa Shewchuk、Arthur Shu、Bartholomew J. Votta、Huiqiang Zhou、John Bertin、Robert W. Marquis

  DOI：10.1021/acsmedchemlett.9b00141

  日期：2019.11.14

  Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant

  在这里，我们报告吡唑并羧酰胺作为受体相互作用蛋白2激酶（RIP2）的新型，有效和激酶选择性抑制剂的发现。基于片段的筛选和设计原理导致了抑制剂系列的鉴定，并使用X射线晶体学分析了关键的结构变化。通过在吡唑环上的N1和C5 N位置进行关键取代，可以实现显着的激酶选择性和效力。桥连的双环吡唑并羧酰胺11代表RIP2的选择性和有效抑制剂，将允许更详细地研究RIP2抑制作为自身炎症性疾病的治疗靶标。
• Catalytic, Regioselective Hydrocarbofunctionalization of Unactivated Alkenes with Diverse C–H Nucleophiles
  作者：Kin S. Yang、John A. Gurak、Zhen Liu、Keary M. Engle

  DOI：10.1021/jacs.6b08850

  日期：2016.11.9

  constructed from two classes of commonly available starting materials, alkenes and carbon-hydrogen (C-H) bonds. The reaction employs a palladium(II) catalyst and utilizes a removable directing group to both control the regioselectivity of carbopalladation and enable subsequent protodepalladation. A wide range of alkenes and C-H nucleophiles, including 1,3-dicarbonyls, aryl carbonyls, and electron-rich aromatics

  形成碳-碳 (CC) 键的反应是有机合成的基石，广泛应用于化学科学。我们报告了一种转化，该转化使 CC 键能够由两类常用的起始材料、烯烃和碳氢 (CH) 键构成。该反应使用钯 (II) 催化剂并利用可去除的导向基团来控制碳钯化的区域选择性并实现随后的原脱钯。广泛的烯烃和 CH 亲核试剂，包括 1,3-二羰基化合物、芳基羰基化合物和富电子芳烃，都是可行的反应伙伴，使迈克尔型反应性从 α,β-不饱和羰基化合物扩展到未活化的烯烃。描述了这种转化在药物多样化和天然产物全合成中的应用。
• [EN] NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE IV, PROCEDE DE PREPARATION DE CES INHIBITEURS ET COMPOSITIONS CONTENANT CES INHIBITEURS
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2006011035A1

  公开（公告）日：2006-02-02

  The present invention relates to novel organic compounds, more particularly, novel Dipeptidyl peptidase IV (DPP-IV) inhibitors of general formula (I) wherein: Y is -S(O)m-, -CH2-, -CHF-, or -CF2; X and Z are independently -C(=O)-, -NR3-, - O- or -S(O)m-; each occurrence of m is independently 0, 1 or 2; a is 0, 1 or 2; b is 0, 1 or 2; the dotted line [----] in the carbocyclic ring represents an optional double bond; R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, or substituted or unsubstituted heteroarylalkyl; R2 is hydrogene, nitrile (-CN), COOH, or an isostere of carboxylic; or analogs, tautomers, enantiomers, diastereomers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, N-oxides, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  该发明涉及新型有机化合物，更特别地，一般式（I）的新型二肽基肽酶IV（DPP-IV）抑制剂，其中：Y为-S(O)m-，-CH2-，-CHF-或-CF2；X和Z独立地为-C(=O)-，-NR3-，-O-或-S(O)m-；m的每次出现独立地为0，1或2；a为0，1或2；b为0，1或2；在碳环中的虚线[----]表示一个可选的双键；R1为取代或未取代的烷基，取代或未取代的烯基，取代或未取代的炔基，取代或未取代的环烷基，取代或未取代的环烷基烷基，取代或未取代的环烯基，取代或未取代的芳基，取代或未取代的芳基烷基，取代或未取代的杂芳基，取代或未取代的杂环烷基，或取代或未取代的杂芳基烷基；R2为氢，腈（-CN），COOH，或羧基的同分异构体；或其类似物，互变异构体，对映异构体，非对映异构体，位置异构体，立体异构体，多晶型，药学上可接受的盐，N-氧化物，药学上可接受的溶剂化合物和含有它们的药物组合物。